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Abstract
Developing vaccines based on viral-like particles (VLPs) can be beneficial. VLPs
represent viral antigens that resemble viruses in nature. Unlike viruses that can
replicate inside their host causing infection, VLPs have no capability to replicate and
cause infection due to the lack of a viral genome. These properties make VLPs a
preferable vaccine rather than inactivated viruses. In this research, VLPs were produced
using a baculovirus infection system. Upon infection in SF9 insect cells, recombinant
baculovirus produces new baculovirus proteins as well as the influenza proteins
hemagglutinin (HA), neuraminidase (NA), and matrix (M1) protein, which can auto
assemble into VLPs. VLPs can be separated from baculovirus using an ultracentrifuge.
The first step of VLP production is selection of the baculovirus with recombinant genes
encoding influenza proteins. The obstacle in selecting recombinant baculovirus is that
infected SF9 cells do not produce specific cytopathogenic effects. To assist in the
observation of baculovirus production in SF9 cells, we developed a protein reporter
system for recombinant baculovirus production. Enhanced green fluorescent protein
(eGFP) was used as a reporter protein. The gene encoding eGFP was cloned into
the same transient plasmid that also encodes HA, NA, and matrix protein M1. Those
proteins were expressed under four different open reading frames. This plasmid was
co-transfected with a linearized baculovirus genome. Structural proteins of baculovirus
and VLP forming recombinant proteins as well as the reporter protein were produced.
Structural proteins of the baculovirus together with the genome of the baculovirus-
containing recombinant genes would co-assemble, producing recombinant baculovirus.
The recombinant proteins then assembled, producing VLPs, and expression of the
reporter protein eGFP would be visible in the cytoplasm by fluorescence microscopy.
Using a TALI cytometer, the percentage of cells that produced GFP was determined
to be 3% of the total population, indicating that eGFP can be used to observe
the production of recombinant baculovirus in SF9 cells. The infectivity of baculovirus
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can be improved by passaging baculovirus in SF9 cells and isolating highly infective
recombinant baculovirus by plaque assays.
Keywords: VLP, Recombinant baculovirus, eGFP
1. Introduction
Although poultry is an H5N1 influenza virus host, this virus can also infect humans with
serious manifestation. Human can be infected by H5N1 by contact with poultry or their
products. Evidence of human-to-human infection does not exist except in ‘family clus-
ter’ cases. The presence of H5N1 infection in poultry and various animals needs to be
watched out. This is based on the ability of the H5N1 virus genome to recombine and
undergo spontaneous mutation, which can alter the virus profile, allowing it to adapt to
horizontal infection [1].
As the chances of human-to-human infection of new strains of H5N1 have increased,
vaccine development is ongoing. One of the H5N1 vaccines developed is a viral-like
particle (VLP). VLPs have a virus-like structure without the viral genome. This influenza
VLP consists of virus surface glycoprotein, hemagglutinin (HA), neuraminidase (NA), and
matrix protein M1. As a multiprotein vaccine, VLPs have advantages compared to sub-
unit or inactivated vaccines. VLPs has a virus-like immunogenicity because the anti-
gens carried have the same antigenic structure as viruses. It is also considered safer
because it does not contain genetic material. The influenza virus has the ability to recom-
bine genomes with other influenza virus subtypes. This recombination will produce new
viruses with new characteristics [2]. Based on this theory, VLPs can be helpful in pre-
venting recombinant viruses with a new genome.
VLPs are made by cloning VLP genes into a transient plasmid. The protein-coding
genes were cloned into one plasmid type in which each protein is expressed under p10
promoter and terminator. Following this, the transient plasmid is co-transfected into SF9
insect cells alongwith the linearized baculovirus genome. In SF9 cells, the transient plas-
mid and linearized baculovirus genome recombine to produce a full baculovirus genome
that produces recombinant baculovirus that contains recombinant protein-producing
genes [3].
There are some issues with the VLP-based vaccine production technique, such as the
observation of baculovirus-infected cells because damaged cells are not evident. In this
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research, an enchanted green fluorescent protein (eGFP) was added to better visualize
recombinant baculovirus. eGFP was expressed separately from the VLP proteins. eGFP
do not encode transmembrane proteins or contain other sequence signals for export to
the outer cell membrane. With this profile, the chance of eGFP remaining on the SF9 cell
lipid bilayer membrane is low, and thus, the expression of eGFP is not linked to VLP.
2. Material and Method
2.1. pBAcH5N1MeGFP plasmid pBAcH5N1MeGFP plasmid
The transient plasmid consisted of VLP-protein coding genes, including HA, NA, M1, and
eGFP. Each plasmid was expressed under a p10 promoter.
Figure 1: Virus-like particle (VLP)-protein coding gene position. VLP and marker on pBacGus 4x. Head of
the arrow: p10 promoter. eGFP: enhanced green fluorescent protein.
2.2. Baculogold and recombinant transient vector coinfection
Baculogold is the linear state of baculovirus DNA. It contains lethal genes and is
unable to produce baculovirus. Baculogold co-transfection with the transient plasmid
recombinant gene carrier resulted in homologous recombination between Baculogold
and the transient vector, with a recombination frequency of approximately 99% in insect
cells. This recombination caused the Baculogold DNA to acquire genes critical for
virus life. Recombination was performed as follows: before transfection, 2 mL of SF9
cells (5x105cells/mL) were plated on a 6-well plate and allowed to adhere. Transfection
reagent was prepared as follows: Mixture 1, 100 ng Bac Vector 1000 (Novagen) mixed
with 500 ng transient plasmid with HA, NA, M1, and eGFP coding genes. SFIII medium
without serum were added until a volume of 25 μLwas reached; Mixture 2, 5 μL of Insect
Genejuce Transfection Reagent 1000 (Novagen) was added into 20 μL of nuclease-free
water (Ambion). After that, mixture 1 was added to mixture 2 and incubated 15 min at
room temperature. During the incubation, cells were washed with sterile phosphate-
buffered saline (PBS). Then, 950 μL SFIII medium without serum (Invitrogen) was added
into mixture 1 and 2, which was then added to SF9 cells. After 1 h at room temperature,
2 mL of media was added. After 4 days at room temperature, SF9 cells were infected
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with the culture supernatants. The remainders of the supernatants were stored at 4∘C
or -80∘C.
2.3. Recombinant baculovirus infection in SF9 cells
SF9 cells were plated on 3 cm diameter plates until confluent. Supernatants containing
the virus were diluted 1:100 and 100 µL was added to monolayer SF9 cells. Infections
were performed for 1 hour and every 15 min cells were shaken to ensure the virus was
spread evenly. Following infection, supernatants were removed and new cell media was
added. Cells were incubated at room temperature for 3–5 days. To increase virus infec-
tivity, viral passages were performed. Cells were observed with a light and fluorescence
microscope. Fluorescence indicated that the cell had been infected with recombinant
baculovirus.
2.4. Tali𝑇𝑀 image-based cytometer
Cells were diluted with PBS to a concentration of 5x105 cells/mL and the number of
fluorescent cells was counted. Then, 25 μL of diluted cells were placed on a Tali slide
(Invitrogen), which was inserted into Tali𝑇𝑀 image-based cytometer (Invitrogen).
3. Result and Discussion
Naturally, baculovirus is a virus that attacks Autographa california (Ac), an alfalfa looper.
Baculovirus is a supercoiled circular double-stranded DNA virus. This genome ranges
in size from 80 to more than 180 kb and encodes approximately 90–180 genes. This
rod-shaped virus is 200 μm long and has a diameter of 30 μm.
Baculovirus has a biphasic life cycle and produces two different phenotypes of
virus progeny: occlusion-derived virions (ODVs) and budded virions (BVs) [4]. ODVs
are derived from occlusion bodies (OBs) and virions inside OBs are called occluded
virions (ODs). BVs originate from virus cell budding. These two virion types differ in
their envelopes and in their ability to infect cells. ODVs or ODs are needed to infect
one larva from another. On the other hand, BVs are needed to infect cultured cells.
ODs are generated from the larva’s body and have been prepared to face external
environmental conditions. The existence of ODs in OVs will make ODs resistant to the
physical, biological, and chemical environment. OBs can allow for the survival of ODs
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for many years in the external environment and do not lose their infectious properties
[5].
Following three viral passages, recombinant baculovirus-infected cells showed some
altered morphologies, including the formation of inclusion bodies and multinucleated
giant cells; cell shape became square; cell clumping; and enlargement. Cell debris was
also observed.
Figure 2: Morphological changes of recombinant baculovirus-infected cells, observed with a light
microscope. (A–E) multinucleated cell (arrow 1), cell debris (arrow 2), clumping cell (arrow 3), inclusion bodies
(arrow 4), and bumps on the cell membrane (arrow 5). None of the morphological changes were observed
in normal cells (F).
The morphological changes of SF9 cells indicated that the recombinant baculovirus
affected these cells. Baculovirus-infected cells will undergo fusion [6]. Fusion of infected
cells results in multinucleated and clumping cells. Baculovirus infection will also induce
cells to enter a resting G2/M phase, resulting in cell death [7]. In general, the disruption
of cell cycle will result in apoptosis, which is evident morphologically by cell swelling.
Following this, protrusions are formed on the cell membrane. After swelling to a certain
volume, cells are fragmented into smaller sizes [8]. This apoptotic phenomenon was also
observed in recombinant baculovirus infected-cells (Figure 2).
The addition of the marker protein eGFP allowed for the differentiation of infected
recombinant baculovirus cells that produce recombinant proteins carried by the bac-
ulovirus. Some studies have investigated the use of eGFP as a baculovirus marker [9].
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In one study, eGFP was expressed as a baculovirus structural protein. The addition of
eGFP has been shown to help in the plaque selection process, which was performed
using UV light at 365 nm. In this research, eGFP was expressed separately, not as part
of the baculovirus structural or VLP proteins. On the third viral passage, approximately
3% of cells were eGFP-positive (Figure 3).
Figure 3: Percentage of eGFP-expressing cells. 1, SF9 cells infected with the third baculovirus passage; 2,
SF9 cell control.
Based on fluorescence microscopy, eGFP fluorescence was not high in intensity (Fig-
ure 4); the intensity was correlated with the molecular amount in cells.
On the fourth passage, an increased number of fluorescent cells were observed (Fig-
ure 5), indicating that more eGFP was expressed. This is hypothesized to be caused by
the recombinant baculovirus, which can produce the recombinant protein, eGFP, with
high intensity.
Thus, recombinant baculovirus was produced, but the capacity to infect was still low,
as indicated by the percentage of fluorescent cells after the third passage. The success
of recombinant baculovirus formation is dependent on the ability of the transient plasmid
to recombine with the linearized baculovirus genome. This recombination occurs in
SF9 cells, producing baculovirus structural proteins and the recombinant baculovirus
genome.
To obtain infectious baculovirus, the plaque test must be performed to screen recom-
binant baculovirus, which has a high infectious ability. In this test, virus isolation from
the plaque is performed. One plaque represents one virus. Each plaque is tested in
terms of recombinant protein producing ability. SDS-PAGE and western blotting can be
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Figure 4: Observation of eGFP by fluorescence microscopy. (A) Third passage of recombinant baculovirus-
infected cells. (B) Control.
Figure 5: Observation of eGFP by fluorescence microscopy. (A) Fourth passage of recombinant baculovirus-
infected cells. (B) Control.
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used to analyze recombinant proteins, and PCR can be performed to determine if the
recombinant baculovirus is present.
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